Basisstatistiken
| CIK | 1393067 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cycclone Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| March 7, 2017 |
China Dasheng Biotechnology FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 333- 141327 CHINA DASHENG BIOTECHNOLOGY CO. (Exact name of registrant as sp |
|
| June 29, 2012 |
CDBT / China Dasheng Biotechnology Co. / Brandt Anna Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. /*/) CHINA DASHENG BIOTECHNOLOGY COMPANY (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 16944C108 (CUSIP Number) Anna G. Brandt c/o LaRue Brandt 789 Meadowbrook Lane Chambersburg, PA 17201 [email protected] (Name, Address, and Em |
